Stifel Initiates Coverage On Neurogene with Buy Rating, Announces Price Target of $31
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis has initiated coverage on Neurogene (NASDAQ:NGNE) with a Buy rating and set a price target of $31.
January 05, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel has initiated coverage on Neurogene with a Buy rating and a price target of $31, indicating a positive outlook for the stock.
Analyst ratings, especially from reputable firms like Stifel, can significantly influence investor sentiment and stock prices. A Buy rating combined with a price target that suggests substantial upside from the current trading price is likely to be viewed positively by investors, potentially leading to a short-term increase in the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100